

Chiara Cremolini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2643748/publications.pdf>

Version: 2024-02-01

189
papers

8,970
citations

76196

40
h-index

48187

88
g-index

194
all docs

194
docs citations

194
times ranked

10492
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>KRAS</i> and <i>BRAF</i> Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2022, 114, 517-527.	3.0	34
2	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 271-279.	3.0	27
3	Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2022, 103, 102326.	3.4	6
4	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 161, 90-98.	1.3	13
5	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with <i>RAS</i> Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. <i>Oncologist</i> , 2022, 27, e29-e36.	1.9	3
6	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O ⁶ -Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1562-1573.	0.8	52
7	Early modulation of Angiotensin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 165, 116-124.	1.3	6
8	The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features. <i>Cancer Treatment Reviews</i> , 2022, 106, 102382.	3.4	9
9	FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , 2022, 167, 23-31.	1.3	8
10	Plasma levels of VEGF and VCAM as predictors of drug-induced hypertension in patients treated with VEGF pathway inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	1.1	1
11	Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series. <i>European Journal of Cancer</i> , 2022, 168, 34-40.	1.3	4
12	KDR genetic predictor of toxicities induced by sorafenib and regorafenib. <i>Pharmacogenomics Journal</i> , 2022, 22, 251-257.	0.9	2
13	Fast, Direct Dihydrouracil Quantitation in Human Saliva: Method Development, Validation, and Application. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6033.	1.2	1
14	Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , 2022, 170, 64-72.	1.3	3
15	Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 876-887.	5.1	83
16	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. <i>British Journal of Cancer</i> , 2022, 127, 957-967.	2.9	6
17	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. <i>Journal of Clinical Oncology</i> , 2022, 40, 2878-2888.	0.8	24
18	Pattern of recurrence and survival after D2 right colectomy for cancer: is there place for a routine more extended lymphadenectomy?. <i>Updates in Surgery</i> , 2022, 74, 1327-1335.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECURSE trial. <i>Tumori</i> , 2021, 107, 353-359.	0.6	5
20	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. <i>British Journal of Cancer</i> , 2021, 124, 183-190.	2.9	7
21	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. <i>Cancer Treatment Reviews</i> , 2021, 92, 102135.	3.4	2
22	Clinical Validation of a Machine-learningâ€‘derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1174-1183.	3.2	28
23	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. <i>Oncologist</i> , 2021, 26, 302-309.	1.9	9
24	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 31-40.	1.3	12
25	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	1.4	3
26	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2021, 21, 285-295.	0.9	3
27	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021, 146, 145-154.	1.3	8
28	Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. <i>Nanomaterials</i> , 2021, 11, 661.	1.9	23
29	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1153-1160.	1.9	1
30	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3234-3242.	3.2	24
31	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. <i>European Journal of Cancer</i> , 2021, 146, 74-83.	1.3	29
32	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e002501.		18
33	Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study. <i>ESMO Open</i> , 2021, 6, 100073.	2.0	12
34	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2021, 11, 12191.	1.6	3
35	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 150, 133-142.	1.3	1
36	Tremellumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. <i>Cancers</i> , 2021, 13, 2839.	1.7	31

#	ARTICLE	IF	CITATIONS
37	Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. <i>Clinical Colorectal Cancer</i> , 2021, 20, 314-317.	1.0	12
38	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. <i>British Journal of Cancer</i> , 2021, 125, 839-845.	2.9	9
39	Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study. <i>Clinical Colorectal Cancer</i> , 2021, , .	1.0	0
40	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e003370.		10
41	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 153, 16-26.	1.3	5
42	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 155, 73-84.	1.3	13
43	Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. <i>Cancers</i> , 2021, 13, 5715.	1.7	6
44	Considerations in the management of younger patients with colorectal cancer.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 16, 1-20.	0.3	0
45	Disease characteristics in younger patients with colorectal cancer.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 16, 6-9.	0.3	0
46	Considerations in the management of younger patients With colorectal cancer: Q&A.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 16, 15-17.	0.3	0
47	Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells. <i>Investigational New Drugs</i> , 2020, 38, 92-98.	1.2	3
48	Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 493-501.	1.2	7
49	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. <i>JCO Precision Oncology</i> , 2020, 4, 1152-1162.	1.5	6
50	Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. <i>Cancers</i> , 2020, 12, 2947.	1.7	4
51	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. <i>PLoS ONE</i> , 2020, 15, e0239439.	1.1	5
52	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy” a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2020, 139, 81-89.	1.3	17
53	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020, 138, 1-10.	1.3	23
54	Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association. <i>ESMO Open</i> , 2020, 5, e001001.	2.0	11

#	ARTICLE	IF	CITATIONS
55	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. , 2020, 8, e001714.		23
56	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. BMC Cancer, 2020, 20, 683.	1.1	53
57	Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?. Clinical Medicine Insights: Oncology, 2020, 14, 117955492094669.	0.6	9
58	Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. Molecular Cancer Therapeutics, 2020, 19, 2146-2154.	1.9	18
59	Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2020, 38, 3314-3324.	0.8	139
60	Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. Cancers, 2020, 12, 2317.	1.7	37
61	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. British Journal of Cancer, 2020, 123, 403-409.	2.9	93
62	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. European Journal of Cancer, 2020, 135, 78-88.	1.3	10
63	Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. ESMO Open, 2020, 5, e000698.	2.0	26
64	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. Scientific Reports, 2020, 10, 9778.	1.6	5
65	KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. Clinical Colorectal Cancer, 2020, 19, 219-225.	1.0	45
66	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncology, The, 2020, 21, 497-507.	5.1	196
67	Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation. Journal of Molecular Diagnostics, 2020, 22, 685-698.	1.2	11
68	Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists's perspective. ESMO Open, 2020, 5, e000759.	2.0	161
69	TRIBE2 results and toxicity " Authors' reply. Lancet Oncology, The, 2020, 21, e300-e301.	5.1	0
70	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. Cancers, 2020, 12, 1742.	1.7	4
71	Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer. International Journal of Cancer, 2020, 146, 2652-2654.	2.3	3
72	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. European Journal of Cancer, 2020, 131, 89-97.	1.3	9

#	ARTICLE	IF	CITATIONS
73	The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis. <i>Cancers</i> , 2020, 12, 1022.	1.7	16
74	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, 191-199.e6.	1.0	20
75	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , 2020, 19, 156-164.	1.0	16
76	Robotic-assisted surgery for colorectal liver metastasis: A single-centre experience. <i>Journal of Minimal Access Surgery</i> , 2020, 16, 160.	0.4	8
77	Universal Pretreatment DPYD Genotyping in Fluoropyrimidine Candidates: Still Controversial but With Clear Instructions for Practitioners, at Last!. <i>JCO Oncology Practice</i> , 2020, 16, 801-802.	1.4	1
78	Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	11
79	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the "BRAF BeCool"™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	1.3	51
80	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1268.	3.4	70
81	CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 121, 593-599.	2.9	24
82	Negative Hyperselection of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 3099-3110.	0.8	65
83	Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. <i>Annals of Oncology</i> , 2019, 30, 1969-1977.	0.6	27
84	Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib. <i>Pharmacogenomics Journal</i> , 2019, 19, 455-464.	0.9	5
85	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. <i>Pharmacogenomics Journal</i> , 2019, 19, 465-472.	0.9	16
86	Quantitative evidence for early metastatic seeding in colorectal cancer. <i>Nature Genetics</i> , 2019, 51, 1113-1122.	9.4	315
87	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 2858.	1.6	38
88	The landscape of d16HER2 splice variant expression across HER2-positive cancers. <i>Scientific Reports</i> , 2019, 9, 3545.	1.6	22
89	Lack of Benefit From Anti-EGFR Treatment in <i>RAS</i> and <i>BRAF</i> Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. <i>Clinical Colorectal Cancer</i> , 2019, 18, 116-124.	1.0	7
90	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. <i>European Journal of Cancer</i> , 2019, 111, 138-147.	1.3	4

#	ARTICLE	IF	CITATIONS
91	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. <i>International Journal of Cancer</i> , 2019, 145, 2082-2090.	2.3	4
92	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. <i>Clinical Colorectal Cancer</i> , 2019, 18, e179-e190.	1.0	12
93	Class 1, 2, and 3 <i>BRAF</i> -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. <i>Clinical Cancer Research</i> , 2019, 25, 3954-3961.	3.2	67
94	Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , 2019, 4, e000489.	2.0	14
95	Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. <i>Biochemical Pharmacology</i> , 2019, 164, 94-105.	2.0	14
96	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 556-563.	0.9	35
97	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019, 109, 175-182.	1.3	25
98	Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. <i>European Journal of Cancer</i> , 2019, 110, 32-41.	1.3	25
99	Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. <i>ESMO Open</i> , 2019, 4, e000496.	2.0	3
100	Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	1.5	1
101	Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2019, 18, e8-e19.	1.0	12
102	Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan. <i>JAMA Oncology</i> , 2019, 5, 343.	3.4	280
103	Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3. <i>Journal of Clinical Oncology</i> , 2019, 37, 594-594.	0.8	0
104	Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE. <i>Journal of Clinical Oncology</i> , 2019, 37, 558-558.	0.8	4
105	Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial. <i>Oncotarget</i> , 2019, 10, 2791-2792.	0.8	0
106	Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2018, 36, 709-714.	1.2	8
107	Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. <i>Annals of Oncology</i> , 2018, 29, 1528-1534.	0.6	83
108	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e471-e488.	1.0	12

#	ARTICLE	IF	CITATIONS
109	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for <i>RAS</i> and <i>BRAF</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 529.	3.4	87
110	Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. <i>Annals of Oncology</i> , 2018, 29, 924-930.	0.6	99
111	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Handâ€œFoot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Clinical Colorectal Cancer</i> , 2018, 17, e395-e414.	1.0	25
112	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018, 118, 955-965.	2.9	17
113	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , 2018, 24, 1082-1089.	3.2	76
114	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. <i>Clinical Cancer Research</i> , 2018, 24, 784-793.	3.2	23
115	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. <i>Nature Communications</i> , 2018, 9, 4112.	5.8	55
116	<i>BRAF</i> V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases. <i>JAMA Surgery</i> , 2018, 153, 1162.	2.2	0
117	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. <i>Oncologist</i> , 2018, 23, 1178-1187.	1.9	46
118	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2018, 18, 623-632.	0.9	8
119	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000403.	2.0	20
120	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2018, 18, 98.	1.1	17
121	The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2298.	1.8	4
122	Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12007-12007.	0.8	13
123	First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3505-3505.	0.8	23
124	Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 581-581.	0.8	3
125	Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the â€œBRAF, BeCoolâ€œ-platform.. <i>Journal of Clinical Oncology</i> , 2018, 36, 639-639.	0.8	2
126	Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2018, 36, 675-675.	0.8	3

#	ARTICLE	IF	CITATIONS
127	<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. <i>Oncotarget</i> , 2018, 9, 7859-7866.	0.8	25
128	Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes to predict clinical benefit of oxaliplatin in FOLFOXIRI plus bevacizumab in TRIBE trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 663-663.	0.8	0
129	Histopathologic response and growth patterns of colorectal cancer liver metastases (CRCLM) in patients treated with triplets plus bevacizumab (bev) or anti-EGFRs.. <i>Journal of Clinical Oncology</i> , 2018, 36, 636-636.	0.8	0
130	Clinical significance of enterocyte-specific gene polymorphisms as candidate marker of oxaliplatin-based treatment for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12066-12066.	0.8	0
131	The impact of Th17 cell pathway-related genetic variants in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15578-e15578.	0.8	0
132	Genetic variation in TET3 and survival in metastatic colorectal cancer (mCRC) from FIRE-3, TRIBE, and MAVERICC clinical trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3575-3575.	0.8	0
133	Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017, 116, 318-323.	2.9	29
134	First-line therapy for mCRC – the influence of primary tumour location on the therapeutic algorithm. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 113-113.	12.5	35
135	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. <i>British Journal of Cancer</i> , 2017, 117, 315-321.	2.9	19
136	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	183
137	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. <i>European Journal of Cancer</i> , 2017, 77, 13-20.	1.3	19
138	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 4312-4322.	3.2	41
139	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2017, 73, 74-84.	1.3	54
140	Tandem repeat variation near the <i>HIC1</i> (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2017, 123, 4506-4514.	2.0	8
141	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , 2017, 2, e000241.	2.0	10
142	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017, 17, 408.	1.1	28
143	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2414-2422.	3.2	148
144	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , 2017, 49, 834-845.	1.3	12

#	ARTICLE	IF	CITATIONS
145	How the Lab is Changing Our View of Colorectal Cancer. <i>Tumori</i> , 2016, 102, 541-547.	0.6	15
146	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT) <i>TJ ETQq0 0 0rgBT /Overabck 10 Tf</i>		
147	A still missing piece of the FIRE-3 puzzle. <i>Lancet Oncology, The</i> , 2016, 17, e515.	5.1	0
148	Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 877-885.	1.3	11
149	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 988-994.	1.9	94
150	Clinical Significance of <i>TLR1</i> I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1740-1745.	1.9	9
151	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 30-36.	2.9	56
152	What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities. <i>PLoS ONE</i> , 2016, 11, e0159146.	1.1	3
153	TRIBE study: are all three cytotoxic drugs crucial? Authors' reply. <i>Lancet Oncology, The</i> , 2015, 16, e578-e579.	5.1	0
154	FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 290-292.	13.9	11
155	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nature Medicine</i> , 2015, 21, 795-801.	15.2	809
156	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 156-166.	2.0	61
157	Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	385
158	First-line chemotherapy for mCRC—a review and evidence-based algorithm. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 607-619.	12.5	138
159	Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: A systematic review and pooled-analysis. <i>European Journal of Cancer</i> , 2015, 51, 800-807.	1.3	46
160	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2374-2381.	1.9	4
161	BRAF-mutated metastatic colorectal cancer between past and future. <i>British Journal of Cancer</i> , 2015, 113, 1634-1635.	2.9	11
162	Single-Agent Panitumumab in Frail Elderly Patients With Advanced <i>RAS</i> and <i>BRAF</i> Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. <i>Oncologist</i> , 2015, 20, 1261-1265.	1.9	42

#	ARTICLE	IF	CITATIONS
163	TAS-102 for the treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2015, 15, 1283-1292.	1.1	12
164	Response. Journal of the National Cancer Institute, 2015, 107, djv205.	3.0	2
165	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncology, The, 2015, 16, 1306-1315.	5.1	835
166	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. Radiotherapy and Oncology, 2015, 117, 315-321.	0.3	28
167	Role of <i>NRAS</i> mutations as prognostic and predictive markers in metastatic colorectal cancer. International Journal of Cancer, 2015, 136, 83-90.	2.3	126
168	Prognostic significance of <i>K-Ras</i> mutation rate in metastatic colorectal cancer patients. Oncotarget, 2015, 6, 31604-31612.	0.8	30
169	KRAS and BRAF genotyping of synchronous colorectal carcinomas. Oncology Letters, 2014, 7, 1532-1536.	0.8	7
170	Biomarkers and Response to Bevacizumab Letter. Clinical Cancer Research, 2014, 20, 1056-1057.	3.2	8
171	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Targeted Oncology, 2014, 9, 205-214.	1.7	27
172	Prevention and management of adverse events related to regorafenib. Supportive Care in Cancer, 2014, 22, 837-846.	1.0	54
173	Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. New England Journal of Medicine, 2014, 371, 1609-1618.	13.9	845
174	Caveolin-1 is a novel regulator of <i>KRAS</i> -dependent migration in colon carcinogenesis. International Journal of Cancer, 2013, 133, 43-57.	2.3	45
175	Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. PLoS ONE, 2013, 8, e66774.	1.1	64
176	Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen. Clinical Colorectal Cancer, 2012, 11, 71-76.	1.0	17
177	Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. Current Colorectal Cancer Reports, 2012, 8, 153-160.	1.0	0
178	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer. Cancer, 2012, 118, 1523-1532.	2.0	34
179	Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. Expert Opinion on Biological Therapy, 2011, 11, 519-531.	1.4	3
180	Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer, 2011, 11, 247.	1.1	69

#	ARTICLE	IF	CITATIONS
181	Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 243-251.	2.0	31
182	Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis. <i>Journal of the National Cancer Institute</i> , 2011, 103, 21-30.	3.0	160
183	Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients. <i>Current Cancer Drug Targets</i> , 2010, 10, 37-45.	0.8	12
184	Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. <i>Pharmacogenomics</i> , 2010, 11, 1247-1256.	0.6	6
185	Predictors of Benefit in Colorectal Cancer Treated With Cetuximab: Are We Getting "Lost in Translation"? <i>Journal of Clinical Oncology</i> , 2010, 28, e173-e174.	0.8	4
186	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. <i>Lancet Oncology</i> , The, 2010, 11, 845-852.	5.1	234
187	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 58.	3.5	46
188	Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009, 1, 167-181.	1.4	7
189	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2622-2629.	0.8	402